FDA Nixes Wider Use Of Rheumatoid Arthritis Drug
The Associated Press
The Food and Drug Administration has rejected an application to expand the use of rheumatoid arthritis treatment Rituxan for patients with earlier stages of the disease, biotech drug developers Genentech Inc. and Biogen Idec said Saturday.
Rituxan is approved to treat patients with moderate-to-severe cases of the disease who are treated first with methotrexate and another class of anti-rheumatic drugs, according to a statement from South San Francisco-based Genentech and Cambridge, Mass.-based Biogen.
The companies had hoped to have the drug approved for use in patients sooner, after they try only methotrexate.But the FDA declined to support the expanded use due to a risk for the potentially fatal brain disease, progressive multifocal leukeoencephalopathy, for which there is no reliable treatment. The companies said that risk is rare. They have reports of three cases of this disease occurring in about 100,000 rheumatoid arthritis patients treated with Rituxan. The FDA also updated the drug's labeling to give doctor's more information on how to treat patients with the drug again, after they have already tried it. A Genentech spokeswoman said the FDA's decision doesn't affect current approvals for the drug, which also treats different types of blood cancer.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV